Email this article Synthesis of Magnetic Nanoparticles Stabilized by Magnetite-Binding Protein for Targeted Delivery to Cancer Cells
- Authors: Kotelnikova P.A.1,2, Shipunova V.O.1,2,3, Aghayeva U.F.4, Stremovskiy O.A.1, Nikitin M.P.1,2, Novikov I.A.5, Schulga A.A.1, Deyev S.M.1,3, Petrov R.V.1
-
Affiliations:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
- Moscow Institute of Physics and Technology (State University)
- National Research Nuclear University “MEPhI,”
- Department of Biological Sciences, Howard Hughes Medical Institute
- Research Institute of Eye Diseases
- Issue: Vol 481, No 1 (2018)
- Pages: 198-200
- Section: Biochemistry, Biophysics, and Molecular Biology
- URL: https://journal-vniispk.ru/1607-6729/article/view/212354
- DOI: https://doi.org/10.1134/S1607672918040051
- ID: 212354
Cite item
Open Access
Access granted
Subscription Access
Abstract
A new method for obtaining biomodified magnetite nanoparticles for targeted delivery to cells was developed. The method is based on the use of the C-terminal fragment of the Mms6 protein, which is involved in the magnetite biomineralization during the synthesis of magnetosomes in magnetotactic bacteria Magnetospirillum magneticum AMB-1, and the barnase*barstar high-affinity protein pair. The Mms6 protein fragment is required for stabilizing magnetite, and the barnase*barstar pair mediates the interaction between nanoparticles and the component for modification. The efficiency of this method was confirmed in the synthesis of magnetite nanoparticles recognizing the HER2/neu tumor marker and in the selective labeling of HER2/neu with these nanoparticles on the surface of cancer cells.
About the authors
P. A. Kotelnikova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Moscow Institute of Physics and Technology (State University)
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow; Dolgoprudnyi, Moscow oblast
V. O. Shipunova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Moscow Institute of Physics and Technology (State University); National Research Nuclear University “MEPhI,”
Author for correspondence.
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow; Dolgoprudnyi, Moscow oblast; Moscow
U. F. Aghayeva
Department of Biological Sciences, Howard Hughes Medical Institute
Email: viktoriya.shipunova@phystech.edu
United States, New York, 10027
O. A. Stremovskiy
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow
M. P. Nikitin
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Moscow Institute of Physics and Technology (State University)
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow; Dolgoprudnyi, Moscow oblast
I. A. Novikov
Research Institute of Eye Diseases
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow
A. A. Schulga
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow
S. M. Deyev
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; National Research Nuclear University “MEPhI,”
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow; Moscow
R. V. Petrov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: viktoriya.shipunova@phystech.edu
Russian Federation, Moscow
Supplementary files
